Intersect ENT, Inc. (NASDAQ:XENT) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02
(e)
2019 Salary Increases and Bonus Plan for Named Executive Officers
On January16, 2019, the Compensation Committee of the Board of Directors (the Compensation Committee) of Intersect ENT, Inc. (theCompany) approved annual salaries and target bonus percentages for 2019 for the Companys Chief Executive Officer, Chief Financial Officer and General Counsel, each a Named Executive Officer (as defined under applicable securities laws). The 2019 compensation information for such executive officers is set forth on Exhibit10.1 to this Current Report on Form8-K, which is incorporated herein by reference.
| 2019 Named Executive Officer Compensation. |
Intersect ENT, Inc. Exhibit
EX-10.1 2 d674568dex101.htm EXHIBIT 10.1 Exhibit 10.1 Exhibit 10.1 2019 Named Executive Officer Compensation Name Base Salary(Annual Rate) (1) Target PerformanceBonus(% of Base Salary) (2) Lisa D. Earnhardt $580,…
To view the full exhibit click here
About Intersect ENT, Inc. (NASDAQ:XENT)
Intersect ENT, Inc. is a commercial stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. It has developed a drug releasing bio-absorbable implant technology that enables targeted and sustained release of therapeutic agents. Its commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. It is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. Its steroid releasing implants are the drug releasing implants for chronic sinusitis sufferers. The PROPEL mini implant is a smaller version of PROPEL and is manufactured from the same bio-absorbable polymer fiber and with the same drug releasing coating and other design characteristics. It also developing NOVA, a steroid releasing implant.